Unknown

Dataset Information

0

Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.


ABSTRACT: Depressive symptoms associated with bipolar disorder negatively impact health-related quality of life (HRQoL). The efficacy of lurasidone in reducing depressive symptoms has been previously demonstrated. The objective of this study was to examine the direct and indirect effect (mediated through improvement in depression symptoms) of lurasidone in improving patient HRQoL.A secondary analysis of data was conducted of two 6-week, double-blind, placebo-controlled trials assessing the effect of lurasidone (lurasidone monotherapy [20-60 mg/day or 80-120 mg/day]; lurasidone adjunctive to lithium or valproate [20-120 mg/day]) in patients with bipolar depression. Patient HRQoL was measured using the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q SF). Depression symptoms were measured using the Montgomery-Asberg Depression Rating Scale (MADRS). Analysis of covariance (ANCOVA) was used to estimate the effect of lurasidone on improvement in the Q-LES-Q SF percentage maximum score from baseline to 6 weeks. Path analysis was used to evaluate the total effect (?1), as well as the indirect (?2*?3) and direct (?4) effect of lurasidone on Q-LES-Q SF change through improvements in MADRS.A total of 340 and 485 patients from the monotherapy and adjunctive therapy, respectively, were included in the analysis. At 6-weeks, ANCOVA analyses demonstrated that lurasidone provided significant improvement in adjusted mean Q-LES-Q SF scores in comparison to placebo for monotherapy (22.9 and 22.7 vs. 15.2, both p?

SUBMITTER: Rajagopalan K 

PROVIDER: S-EPMC4877991 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.

Rajagopalan Krithika K   Bacci Elizabeth Dansie ED   Ng-Mak Daisy D   Wyrwich Kathy K   Pikalov Andrei A   Loebel Antony A  

BMC psychiatry 20160523


<h4>Background</h4>Depressive symptoms associated with bipolar disorder negatively impact health-related quality of life (HRQoL). The efficacy of lurasidone in reducing depressive symptoms has been previously demonstrated. The objective of this study was to examine the direct and indirect effect (mediated through improvement in depression symptoms) of lurasidone in improving patient HRQoL.<h4>Methods</h4>A secondary analysis of data was conducted of two 6-week, double-blind, placebo-controlled t  ...[more]

Similar Datasets

| S-EPMC7756283 | biostudies-literature
| S-EPMC4792823 | biostudies-literature
| S-EPMC3936838 | biostudies-literature
| S-EPMC5506697 | biostudies-literature
| S-EPMC8568779 | biostudies-literature
| S-EPMC4888300 | biostudies-literature
| S-EPMC7722645 | biostudies-literature
| S-EPMC5657395 | biostudies-literature
| S-EPMC5475665 | biostudies-literature
| S-EPMC10324333 | biostudies-literature